Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

929 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selumetinib in the treatment of non-small-cell lung cancer.
Bernabé R, Patrao A, Carter L, Blackhall F, Dean E. Bernabé R, et al. Among authors: dean e. Future Oncol. 2016 Nov;12(22):2545-2560. doi: 10.2217/fon-2016-0132. Epub 2016 Jul 28. Future Oncol. 2016. PMID: 27467210 Review.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R. Jamieson D, et al. Among authors: dean e. Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28. Eur J Cancer. 2016. PMID: 27693888 Free article. Clinical Trial.
Malignant bowel obstruction in advanced ovarian cancer.
Dean E, Khoja L, Clamp A, Jayson GC, Goonetilleke D, Conway AM, Hasan J. Dean E, et al. Future Oncol. 2017 Mar;13(6):513-521. doi: 10.2217/fon-2016-0431. Epub 2017 Jan 18. Future Oncol. 2017. PMID: 28095701
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Greystoke A, Steele N, Arkenau HT, Blackhall F, Md Haris N, Lindsay CR, Califano R, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E. Greystoke A, et al. Among authors: dean e. Br J Cancer. 2017 Sep 26;117(7):938-946. doi: 10.1038/bjc.2017.271. Epub 2017 Aug 24. Br J Cancer. 2017. PMID: 28950288 Free PMC article. Clinical Trial.
Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging.
Salem A, Mistry H, Backen A, Hodgson C, Koh P, Dean E, Priest L, Haslett K, Trigonis I, Jackson A, Asselin MC, Dive C, Renehan A, Faivre-Finn C, Blackhall F. Salem A, et al. Among authors: dean e. Clin Lung Cancer. 2018 May;19(3):239-248.e7. doi: 10.1016/j.cllc.2017.12.002. Epub 2017 Dec 11. Clin Lung Cancer. 2018. PMID: 29398577 Free PMC article.
929 results